|
1
|
Islami F, Torre LA and Jemal A: Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 4:3272015.PubMed/NCBI
|
|
2
|
Lin HT, Liu FC, Wu CY, Kuo CF, Lan WC and Yu HP: Epidemiology and survival outcomes of lung cancer: A population-based study. Biomed Res Int. 2019:81481562019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schabath MB and Cote ML: Cancer progress and priorities: Lung cancer. Cancer Epidemiol Biomarkers Prev. 28:1563–1579. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proceedings. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xue X, Liu Y, Wang Y, Meng M, Wang K, Zang X, Zhao S, Sun X, Cui L, Pan L and Liu S: MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget. 7:84508–84519. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu Y, Qiu Y, Yagüe E, Ji W, Liu J and Zhang J: miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis. 7:e22912016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mraz M, Malinova K, Mayer J and Pospisilova S: MicroRNA isolation and stability in stored RNA samples. Biochem Biophys Res Commun. 390:1–4. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Glinge C, Clauss S, Boddum K, Jabbari R, Jabbari J, Risgaard B, Tomsits P, Hildebrand B, Kääb S, Wakili R, et al: Stability of circulating blood-based microRNAs-pre-analytic methodological considerations. PLoS One. 12:e01679692017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:2032017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bajan S and Hutvagner G: RNA-based therapeutics: From antisense oligonucleotides to miRNAs. Cells. 9:1372020. View Article : Google Scholar
|
|
14
|
Fabbri M: MicroRNAs and cancer: Towards a personalized medicine. Curr Mol Med. 13:751–756. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Florczuk M, Szpechcinski A and Chorostowska-Wynimko J: miRNAs as biomarkers and therapeutic targets in non-small cell lung cancer: Current perspectives. Target Oncol. 12:179–200. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rayan A, Raiyn J and Falah M: Nature is the best source of anticancer drugs: Indexing natural products for their anticancer bioactivity. PLoS One. 12:e01879252017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sharifi-Rad J, Ozleyen A, Boyunegmez Tumer T, Oluwaseun Adetunji C, El Omari N, Balahbib A, Taheri Y, Bouyahya A, Martorell M, Martins N and Cho WC: Natural products and synthetic analogs as a source of antitumor drugs. Biomolecules. 9:6792019. View Article : Google Scholar
|
|
18
|
Yu SM and Kim SJ: Production of reactive oxygen species by withaferin A causes loss of type collagen expression and COX-2 expression through the PI3K/Akt, p38, and JNK pathways in rabbit articular chondrocytes. Exp Cell Res. 319:2822–2834. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roy RV, Suman S, Das TP, Luevano JE and Damodaran C: Withaferin A, a steroidal lactone from Withania somnifera, induces mitotic catastrophe and growth arrest in prostate cancer cells. J Nat Prod. 76:1909–1915. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stan SD, Zeng Y and Singh SV: Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutr Cancer. 60 (Suppl 1):S51–S60. 2008. View Article : Google Scholar
|
|
21
|
Mayola E, Gallerne C, Degli Esposti D, Esposti DD, Martel C, Pervaiz S, Larue L, Debuire B, Lemoine A, Brenner C and Lemaire C: Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2. Apoptosis. 16:1014–1027. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fong MY, Jin S, Rane M, Singh RK, Gupta R and Kakar SS: Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLoS One. 7:e422652012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cai Y, Sheng ZY, Chen Y and Bai C: Effect of withaferin A on A549 cellular proliferation and apoptosis in non-small cell lung cancer. Asian Pac J Cancer Prev. 15:1711–1714. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Oh JH, Lee TJ, Kim SH, Choi YH, Lee SH, Lee JM, Kim YH, Park JW and Kwon TK: Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation. Apoptosis. 13:1494–1504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu Y, Hamza A, Zhang T, Gu M, Zou P, Newman B, Li Y, Gunatilaka AA, Zhan CG and Sun D: Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol. 79:542–551. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hahm ER, Lee J, Huang Y and Singh SV: Withaferin a suppresses estrogen receptor-α expression in human breast cancer cells. Mol Carcinog. 50:614–624. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kyakulaga AH, Aqil F, Munagala R and Gupta RC: Withaferin a inhibits epithelial to mesenchymal transition in non-small cell lung cancer cells. Sci Rep. 8:157372018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grogan PT, Sleder KD, Samadi AK, Zhang H, Timmermann BN and Cohen MS: Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways. Invest New Drugs. 31:545–557. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hsu JH, Chang PM, Cheng TS, Kuo YL, Wu AT, Tran TH, Yang YH, Chen JM, Tsai YC, Chu YS, et al: Identification of withaferin A as a potential candidate for anti-cancer therapy in non-small cell lung cancer. Cancers (Basel). 11:10032019. View Article : Google Scholar
|
|
30
|
Strober W: Trypan blue exclusion test of cell viability. Curr Protoc Immunol. 21:A. 3B. 1–A. 3B. 2. 1997.
|
|
31
|
Ernst O and Zor T: Linearization of the Bradford protein assay. J Vis Exp. 19182010.
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu CC, Huang KF, Yang TY, Li YL, Wen CL, Hsu SL and Chen TH: The topoisomerase 1 inhibitor austrobailignan-1 isolated from Koelreuteria Henryi induces a G2/M-phase arrest and cell death independently of p53 in non-small cell lung cancer cells. PLoS One. 10:e01320522015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP and Looi CY: The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges. Cells. 8:11182019. View Article : Google Scholar
|
|
35
|
Liang G, Ding M, Lu H, Cao NA, Niu Y, Gao Y and Lu J: Metformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration. Oncol Lett. 10:1527–1532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW and Weinberg RA: Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 28:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang R, He Y, Zhang X, Xing B, Sheng Y, Lu H and Wei Z: Estrogen receptor-regulated microRNAs contribute to the BCL2/BAX imbalance in endometrial adenocarcinoma and precancerous lesions. Cancer Lett. 314:155–165. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Oh JH and Kwon TK: Withaferin A inhibits tumor necrosis factor-α-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells. Int Immunopharmacol. 9:614–619. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou YF, Yu XT, Yao JJ, Xu CW, Huang JH, Wan Y and Wu MJ: Withaferin A inhibits hepatoma cell proliferation through induction of apoptosis and cell cycle arrest. Int J Clin Exp Pathol. 9:12381–12389. 2016.
|
|
40
|
Chang HW, Li RN, Wang HR, Liu JR, Tang JY, Huang HW, Chan YH and Yen CY: Withaferin A induces oxidative stress-mediated apoptosis and DNA damage in oral cancer cells. Front Physiol. 8:6342017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lv TZ and Wang GS: Antiproliferation potential of withaferin A on human osteosarcoma cells via the inhibition of G2/M checkpoint proteins. Exp Therap Med. 10:323–329. 2015. View Article : Google Scholar
|
|
42
|
Thaiparambil JT, Bender L, Ganesh T, Kline E, Patel P, Liu Y, Tighiouart M, Vertino PM, Harvey RD, Garcia A and Marcus AI: Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int J Cancer. 129:2744–2755. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mello SS and Attardi LD: Deciphering p53 signaling in tumor suppression. Curr Opin Cell Biol. 51:65–72. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Braithwaite A and Prives C: p53: More research and more questions. Cell Death Differ. 13:877–880. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wu M, Ye H, Tang Z, Shao C, Lu G, Chen B, Yang Y, Wang G and Hao H: p53 dynamics orchestrates with binding affinity to target genes for cell fate decision. Cell Death Dis. 8:e31302017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang TY, Teng CLJ, Lin TCC, Chen KC, Hsu SL and Wu CC: Transcriptional repression of Aurora-A gene by wild-type p53 through directly binding to its promoter with histone deacetylase 1 and mSin3a. Int J Cancer. 142:92–108. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Muller PA and Vousden KH: p53 mutations in cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lu C and El-Deiry WS: Targeting p53 for enhanced radio-and chemo-sensitivity. Apoptosis. 14:597–606. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
He C, Li L, Guan X, Xiong L and Miao X: Mutant p53 gain of function and chemoresistance: The role of mutant p53 in response to clinical chemotherapy. Chemotherapy. 62:43–53. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sheedy P and Medarova Z: The fundamental role of miR-10b in metastatic cancer. Am J Cancer Res. 8:1674–1688. 2018.PubMed/NCBI
|
|
51
|
Li X, Xu M, Ding L and Tang J: MiR-27a: A novel biomarker and potential therapeutic target in tumors. J Cancer. 10:2836–2848. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li X, Liu X, Xu W, Zhou P, Gao P, Jiang S, Lobie PE and Zhu T: c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2. J Biol Chem. 288:18121–18133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Riley T, Sontag E, Chen P and Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 9:402–412. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF and Minna JD: p53: A frequent target for genetic abnormalities in lung cancer. Science. 246:491–494. 1989. View Article : Google Scholar : PubMed/NCBI
|
